Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.5696
- Book/Share 9.1268
- PB 5.9528
- Debt/Equity 2.7512
- CurrentRatio 1.2663
- ROIC 0.1414
- MktCap 110317456533.0
- FreeCF/Share 7.5085
- PFCF 7.2093
- PE 18.2873
- Debt/Assets 0.5268
- DivYield 0.0458
- ROE 0.3465
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BMY | BofA Securities | Neutral | Buy | -- | $61 | Dec. 15, 2025 |
| Upgrade | BMY | Guggenheim | Neutral | Buy | -- | $62 | Dec. 12, 2025 |
| Initiation | BMY | Scotiabank | -- | Sector Perform | -- | $45 | Nov. 13, 2025 |
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.
Read More
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Published: December 19, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
Published: December 15, 2025 by: Benzinga
Sentiment: Positive
BofA Securities upgraded Bristol Myers Squibb & Co. (NYSE: BMY), citing near-term catalysts.
Read More
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
Read More
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Read More
5 Blue Chip Stocks to Buy Now That Pay Reliable 4%+ Dividends
Published: December 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential.
Read More
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
Read More
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
Read More
A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.
Published: December 03, 2025 by: Market Watch
Sentiment: Positive
Bristol Myers' stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer's treatment, even though the outcome of a late-stage trial has been delayed.
Read More
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
Published: December 03, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)-- #biotech--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol Myers Squibb Stock Climbs on Alzheimer's Trial Update. What to Know.
Published: December 03, 2025 by: Barrons
Sentiment: Positive
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer's disease.
Read More
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
What Is Happening With BMY Stock?
Published: December 01, 2025 by: Forbes
Sentiment: Positive
Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 billion.
Read More
8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills
Published: November 28, 2025 by: Seeking Alpha
Sentiment: Positive
Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result in higher yields; eight of the top ten are already at ideal pricing levels.
Read More
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
Read More
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
Read More
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
Read More
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers.
Read More
Why Bristol-Myers Squibb Remains Undervalued In 2025
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb remains my favorite, almost the only Big Pharma stock that hasn't left the accumulation zone. Sales of its "gem" in the cardiovascular franchise, Camzyos, were $296 million in Q3, up 89.7% year-over-year. On the other hand, my concerns about Opdivo Qvantig did not materialize, as its sales reached $67 million, double the Q2 figures.
Read More
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
Read More
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
Read More
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100